Pasotuxizumab

Product Name: Pasotuxizumab
CAS No.: 1442657-12-6
Chemical Name: Pasotuxizumab
Synonyms: Pasotuxizumab;Research Grade Pasotuxizumab;Research Grade Pasotuxizumab (DHG01301)
CBNumber: CB58080908
Formula Weight: 0
MOL File: Mol file

More

Less

Pasotuxizumab Property

form: Liquid
color: Colorless to light yellow

More

Less

Hazard and Precautionary Statements (GHS)

More

Less

Pasotuxizumab Chemical Properties,Usage,Production

Uses

Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC)[1][2].

in vivo

Pasotuxizumab (0-100 ng/mL approximately, 48 h) leads to activation of CD4+ and CD8+ T cell populations, with EC₅₀s of 3.4-6.7 ng/mL for human cocultures, and 13.7-21.2 ng/mL for cynomolgus monkey cell cocultures^[2].
Pasotuxizumab (0-100 ng/mL approximately, 48 h) increases release of interferon-γ, TNF-α, IL-2 and IL-10 in T cells^[2].

Animal Model:	PC-3-huPSMA mouse xenograft model^[2]
Dosage:	0.005-5 mg/kg
Administration:	i.v., once daily
Result:	Inhibited tumor growth by 86% (0.005 mg/kg/d) and 99% (5 mg/kg/d).

Animal Model:

BALB/c mice (PK Assay)^[2]

Dosage:

0.1, 0.3, and 1 mg/kg

Administration:

i.v. bolus administration or s.c.

Result:

Pharmacokinetic profile of Rafivirumab.

Dose (mg/kg)	AUC (mg h/L)	CL_matrix (L/h/kg)	T_1/2 (h)	F (%)
i.v. (0.3)	0.93	0.32	9.7	100
s.c. (0.3)	0.17		11	18

References

[1] Horst-Dieter Hummel, et al. Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology 2019 37:15_suppl, 5034-5034.
[2] Friedrich M, et al. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol Cancer Ther. 2012 Dec;11(12):2664-73. DOI:10.1158/1535-7163.MCT-12-0042

Pasotuxizumab Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

Pasotuxizumab Suppliers

China 10 Global 10

ShangHai Biochempartner Co.,Ltd

Tel: 177-54423994 17754423994
Fax: QQ:2853530913
Email: 2853530910@QQ.com
Country: China
ProdList: 8000
Advantage: 62

Wuhan Chemstan Biotechnology Co., Ltd.

Tel: 027-65317797 15926423062
Fax: QQ：422450190
Email: 422450190@qq.com
Country: China
ProdList: 10308
Advantage: 58

Biolab Reagents

Tel: 027-65279366 18108604356
Email: products@biolabreagent.com
Country: China
ProdList: 9868
Advantage: 58

Wuhan Jingkangen Biomedical Technology Co., Ltd

Tel: 13720134139 086-15871494362 13720134139
Email: orders@jknbiochem.com
Country: China
ProdList: 6762
Advantage: 58

Shanghai Yifei Biotechnology Co. , Ltd.

Tel: 021-65675885 18964387627
Email: customer_service@efebio.com
Country: China
ProdList: 11973
Advantage: 58

Changsha Fuzhen Biotechnology Co.，LTD

Tel: 0731-13823398 15111215862
Email: 313359644@qq.com
Country: China
ProdList: 4161
Advantage: 58

Atagenix Laboratories

Tel: 027-87008169 17762441161
Email: info@atagenix.com
Country: China
ProdList: 10001
Advantage: 58

AntibodySystem Laboratories SAS

Tel: 33175446423
Email: support@antibodysystem.com
Country: China
ProdList: 6739
Advantage: 58

Biosynth Biological Technology (Suzhou) Co Ltd

Tel: 51288865780
Email: sales@biosynth.com
Country: China
ProdList: 6051
Advantage: 58

Cell Sciences

Tel: 9785721070
Email: info@cellsciences.com
Country: China
ProdList: 6308
Advantage: 58

1442657-12-6, PasotuxizumabRelated Search:

Timigutuzumab Gedivumab Praluzatamab Tirnovetmab Envafolimab Ragifilimab Manfidokimab Feladilimab Carotuximab Licaminlimab

Pasotuxizumab

Research Grade Pasotuxizumab (DHG01301)

Research Grade Pasotuxizumab

1442657-12-6